Other Events ·
Ultragenyx completes $210M PRV sale and announces $25M restructuring with 20% workforce reduction
RAREUltragenyx Pharmaceutical Inc.
Ultragenyx completed the sale of a Priority Review Voucher for $210 million, receiving gross proceeds upon closing. The company also announced a restructuring plan involving a 20% workforce reduction to reduce expenses, estimating approximately $25 million in total charges primarily related to severance and employee-related costs. These actions are expected to drive at least a 50% reduction in 2027 R&D expenses compared to 2025 levels. Ultragenyx is a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases.